Infliximab in the therapy of rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2007-60-65
Abstract
Objective. To assess efficacy and tolerability of infliximab in pts with rheumatoid arthritis (RA) in real clinical practice.
Materials and methods. 75 RA pts with high disease activity according to DAS 28 in 80% who received previous antirheumatic drugs without proper effect were included in an open clinical trial. DAS 28 and ACR criteria were used as primary outcome measures.
Results. Infliximab administration provided significant clinical improvement in most pts. Already in a week after the first infusion 20% ACR improvement was achieved in 74% of pts. Significant improvement of all the main treatment effect parameters was achieved after the second infusion. ESR and CRP mean values normalized after the third infusion. Rheumatoid factor decrease was noted after 6 weeks. Mean values of tender and swollen joint counts significantly decreased but arthritis signs remained in a part of pts. Clinical remission was achieved in 4 (19%) from 21 pts completed a year’s course of treatment and in 4 pts the treatment was not effective. Serious adverse events requiring infliximab withdrawal (including infectious arthritis, hand phlegmon and bronchitis) appeared in 7 pts
Conclusion. These results show high efficacy of infliximab and prove advisability of its administration in RA
About the Authors
G. V. Lukina
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
Y. A. Sigidin
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
E. S. Posdnyakova
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
E. L. Luchihina
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
D. E. Karateev
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
E. L. Nasonov
ГУ Институт ревматологии РАМН, Москва
Russian Federation
Russian Federation
References
1. Maini R.N., St Clair E.W., Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet , 1999, 354, 932-939.
2. Lipsky P., Heijde van der D., St Clair E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl.J.Med., 2000, 343, 1594-1602.
3. Furst D., Keystone E., Breedveld F. et al. Updated consensus statement on tumour necrosis factor blocking agent for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann.Rheum. Dis., 2001, 60, suppl.III, iii 2-5.
4. Furst D., Keystone E., Breedveld F. et al. Updated consensus statement on tumour necrosis factor blocking agent for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann.Rheum. Dis., 2001, 60, suppl.III, iii 2-5.
5. Ostergaard M., Unkerskov J., Krogh N.S. et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treаted with infliximab or etanercept – results from the nationwide danish “danbio” database. Ann.Rheum.Dis., 2005, 64, 59- 60.
6. Quinn M.A., Conaghan P.G., Greenstein A. et al. Sustained response in early poor prognosis RA after withdrawal of infliximab therapy. Arthr.Rheum., 2002, 46, 3416.
7. Breedveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum.Dis., 2004, 63, 149-155.
8. Van der Bijl A.E., Goekoop-Ruiterman Y.P., Breedveld F.C. et al. Many early rheumatoid arthritis patients with a good clinical response to infliximab can discontinue anti-TNF-alpha therapy without relapse. Ann.Rheum.Dis., 2005, 64, suppl.III, 59.
9. De Vries-Bouwsta J.K., Goekoop-Ruiterman Y., van Zeben D. et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeST trial. Ann.Rheum.Dis., 2004, 63, suppl.1, S58
10. Bathon J., Martin R.W., Fleischmann R.M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N.Engl. J.Med., 2000, 343, 1586-1593.
11. Genovese M.C., Martin R.W., Fleishmann R.M. et al. Etanercept (Enbrel) in early erosive rheumatoid arthritis (Era Trial): 5-year clinical and radiographic data. Arthr.Rheum., 2003, 48, suppl., S122.
12. Keystone E., Kavanaugh A., Fischkoff S. Response to adalimumab in patients with early versus late rheumatoid arthritis (RA). Ann.Rheum.Dis., 2003, 62, suppl. 1., 170.
13. Smolen J.S., Han C., Bala M. et al. Infliximab consistently induces clinical remission in patients with early active rheumatoid arthritis regardless of remission criteria. Arthr.Rheum., 2005, 52 suppl., S139.
14. Van der Heijde D., Emery P., Keystone E.C. et al. Effect of Infliximab and methotrexate on radiographic progression in patients with early rheumatoid arthritis. Arthr.Rheum., 2005, 52 suppl, S139- 140.
15. Lequerre T., Vittecog O., Kemmer N. et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis. J.Rheumatol., 2006, 33, 1307-1314.
Review
For citations:
Lukina G.V., Sigidin Y.A., Posdnyakova E.S., Luchihina E.L., Karateev D.E., Nasonov E.L. Infliximab in the therapy of rheumatoid arthritis. Rheumatology Science and Practice. 2007;45(4):60-65. (In Russ.) https://doi.org/10.14412/1995-4484-2007-60-65
Views:
1427
Email this article 